2. Search Result
Search Result
Results for "

lung fibrosis

" in MedChemExpress (MCE) Product Catalog:

59

Inhibitors & Agonists

2

Screening Libraries

2

Biochemical Assay Reagents

8

Peptides

2

Natural
Products

3

Isotope-Labeled Compounds

2

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-48917
    C10 Bisphosphonate

    		Phospholipase Inflammation/Immunology
    C10 Bisphosphonate is an inhibitor for acid sphingomyelinase. C10 Bisphosphonate is promising for research of inflammatory lung diseases, cystic fibrosis and atherosclerosis .
    C10 Bisphosphonate
  • HY-12678
    Entrectinib
    Maximum Cited Publications
    21 Publications Verification

    NMS-E628; RXDX-101

    		 ROS Kinase Trk Receptor Anaplastic lymphoma kinase (ALK) Autophagy Cancer
    Entrectinib (NMS-E628) is an orally active, BBB-penetrated and centrally active inhibitor of TrkA/B/C, ROS1 and ALK, with IC50 values of 1, 3, 5, 12 and 7 nM, respectively. Entrectinib induces apoptosis and cycle arrest in cancer cells, has antitumor activity, and attenuates bleomycin-induced lung fibrosis in mice .
    Entrectinib
  • HY-155191
    Galectin-3/galectin-8-IN-1

    		Galectin Inflammation/Immunology Cancer
    Galectin-3/galectin-8-IN-1 (Compound 53) is a dual Galectin-3 and galectin-8 C-terminal domain inhibitor, with Kd values of 4.12 μM and 6.04 μM respectively. Galectin-3/galectin-8-IN-1 inhibits the MRC-5 lung fibroblast cells migration. Galectin-3/galectin-8-IN-1 can be used for research of cancer and tissue fibrosis .
    Galectin-3/galectin-8-IN-1
  • HY-143237
    ATX inhibitor 11

    		Phosphodiesterase (PDE) Others
    ATX inhibitor 11 (compound 13c) is a potent ATX (autotaxin) inhibitor, with an IC50 of 2.7 nM. ATX inhibitor 11 can typically alleviate the severity of fibrosis tissues and effectively reduce the deposition of fibrotic biomarker α-SMA in mice fibrosis model. ATX inhibitor 11 can be used for lung fibrosis research .
    ATX inhibitor 11
  • HY-143420
    ATX inhibitor 15

    		Phosphodiesterase (PDE) Inflammation/Immunology
    ATX inhibitor 15 (compound 30), a indole-based carbamate derivative, is a potent autotaxin (ATX) inhibitor with an IC50 of 2.17 nM. ATX inhibitor 15 inhibits in vivo ATX and the gene expression of pro-fibrotic factors. ATX inhibitor 15 has lung protection effects in Bleomycin challenged mice lung fibrosis model .
    ATX inhibitor 15
  • HY-155593
    JNK-1-IN-2

    		JNK Inflammation/Immunology
    JNK-1-IN-2 (Compound c6) is a JNK-1 inhibitor (IC50: 33.5 nM). JNK-1-IN-2 also inhibits JNK-2 and JNK-3 with IC50s of 112.9 nM and 33.2 nM. JNK-1-IN-2 inhibits the phosphorylation of c-Jun. JNK-1-IN-2 reverses lung impairment. JNK-1-IN-2 can be used for research of pulmonary fibrosis .
    JNK-1-IN-2
  • HY-155192
    Galectin-3/galectin-8-IN-2

    		Galectin Inflammation/Immunology Cancer
    Galectin-3/galectin-8-IN-2 (Compound 57) is a dual Galectin-3 and galectin-8 C-terminal domain inhibitor, with Kd values of 12.8 μM and 2.06 μM respectively. Galectin-3/galectin-8-IN-2 inhibits the MRC-5 lung fibroblast cells migration. Galectin-3/galectin-8-IN-2 can be used for research of cancer and tissue fibrosis .
    Galectin-3/galectin-8-IN-2
  • HY-12678R
    Entrectinib (Standard)

    		ROS Kinase Trk Receptor Anaplastic lymphoma kinase (ALK) Autophagy Cancer
    Entrectinib (Standard) is the analytical standard of Entrectinib. This product is intended for research and analytical applications. Entrectinib (NMS-E628) is an orally active, BBB-penetrated and centrally active inhibitor of TrkA/B/C, ROS1 and ALK, with IC50 values of 1, 3, 5, 12 and 7 nM, respectively. Entrectinib induces apoptosis and cycle arrest in cancer cells, has antitumor activity, and attenuates bleomycin-induced lung fibrosis in mice .
    Entrectinib (Standard)
  • HY-129213
    CL-242817

    		Angiotensin-converting Enzyme (ACE) Cardiovascular Disease Others
    CL-242817 is an orally available angiotensin converting enzyme (ACE) inhibitor. CL-242817 inhibits the conversion of angiotensin I to angiotensin II and has blood pressure lowering activity. CL-242817 can also improve Monocrotaline (HY-N0750) induced lung injury. CL-242817 can be used in the study of pulmonary fibrosis and hypertension-related diseases .
    CL-242817
  • HY-137992
    Aucuparin

    		Others Inflammation/Immunology
    Aucuparin, a natural product found in Sorbus aucuparia, inhibits pulmonary fibrosis in a bleomycin (BLM)-induced lung fibrosis mouse model. Anti-inflammatory activity .
    Aucuparin
  • HY-139786
    Cofirasersen

    ION-827359

    		 Sodium Channel Others
    Cofirasersen is designed to reduce the expression of ENaC in the lung. ENaC is a sodium transport channel and believed to be hyperactive in cystic fibrosis, which is caused by mutations in the cystic fibrosis transmembrane regulator gene.
    Cofirasersen
  • HY-139786A
    Cofirasersen sodium

    ION-827359 sodium

    		 Sodium Channel Others
    Cofirasersen sodium is designed to reduce the expression of ENaC in the lung. ENaC is a sodium transport channel and believed to be hyperactive in cystic fibrosis, which is caused by mutations in the cystic fibrosis transmembrane regulator gene.
    Cofirasersen sodium
  • HY-169071S
    ATX-1905

    		Phosphodiesterase (PDE) Others
    ATX-1905 is a positron emission tomography (PET) tracer that demonstrates good autotaxin (ATX) binding specificity and achieves semiquantification of lung ATX expression levels, which are elevated in fibrotic lungs. ATX-1905 exhibits elevated uptake in Bleomycin (HY-108345)-induced pulmonary fibrosis (BPF) lungs. ATX-1905 is promising for research of idiopathic pulmonary fibrosis (IPF) .
    ATX-1905
  • HY-108464A
    Phenamil methanesulfonate

    		Sodium Channel TRP Channel Metabolic Disease Inflammation/Immunology
    Phenamil methanesulfonate, an analog of Amiloride (HY-B0285), is a more potent and less reversible epithelial sodium channel (ENaC) blocker with an IC50 of 400 nM . Phenamil methanesulfonate is also a competive inhibitor of TRPP3 and inhibits TRPP3-mediated Ca 2+ transport with an IC50 of 140 nM in a Ca 2+ uptake assay . Phenamil methanesulfonate is an intriguing small molecule to promote bone repair by strongly activating BMP signaling pathway . Phenamil methanesulfonate is used for the research of cystic fibrosis lung disease .
    Phenamil methanesulfonate
  • HY-147936
    TP0556351

    		MMP Inflammation/Immunology
    TP0556351 is a potent and selective matrix metalloproteinase-2 (MMP2) inhibitor with an IC50 value of 0.2 nM. TP0556351 reduces the amount of collagen in the lungs of a Bleomycin-induced pulmonary fibrosis mouse model. TP0556351 can be used for researching idiopathic pulmonary fibrosis (IPF) .
    TP0556351
  • HY-123493
    P552-02 mesylate

    552-02

    		 Others Inflammation/Immunology
    P552-02 (552-02) mesylate is a sodium channel blocker that is potentially used for the treatment of cystic fibrosis, exhibiting biological activity that enhances mucociliary clearance in the lungs while minimizing the risk of hyperkalaemia.
    P552-02 mesylate
  • HY-145603
    Vanzacaftor

    VX-121

    		 CFTR Chloride Channel Neurological Disease
    Vanzacaftor (VX-121) is an orally active noval corrector of Cystic fibrosis transmembrane conductance regulator (CFTR). Vanzacaftor improves processing and trafficking of CFTR protein as well as increases chloride transport in triple combined with Tezacaftor (HY-15448) and Deutivacaftor. Vanzacaftor-Tezacaftor-Deutivacaftor is safe and well tolerated, improving lung function, respiratory symptoms, and CFTR function with cystic fibrosis, which is promising for research in the field of cystic fibrosis diseases .
    Vanzacaftor
  • HY-123522
    PAT-048

    		Phosphodiesterase (PDE) Inflammation/Immunology
    PAT-048 is a potent, selective and orally active autotaxin inhibitor, inhibits IL-6 mRNA expression, but shows no effect on autotaxin protein and pulmonary lysophosphatidic acid (LPA) production in lung fibrosis model. PAT-048 shows an IC50 and IC90 of 20 nM and 200 nM for autotaxin in mouse plasma. PAT-048 reduces dermal fibrosis in vivo .
    PAT-048
  • HY-169226
    HDAC6-IN-51

    		HDAC Inflammation/Immunology
    HDAC6-IN-51 (Compound 7e) is a selective HDAC6 inhibitor with an IC50 value of 42.9 nM. HDAC6-IN-51 exhibits good anti-lung fibrosis activity .
    HDAC6-IN-51
  • HY-151164
    LasR-IN-2

    		Bacterial Infection
    LasR-IN-2 is a LasR inhibitor that forms H-bonding with TRY-56 residue. LasR-IN-2 can be used in the research of bacterial infection, neutropenia, severe burns and chronic lung disease in cystic fibrosis (CF) .
    LasR-IN-2
  • HY-162496
    L-NBDNJ

    		Bacterial Infection Inflammation/Immunology
    L-NBDNJ, a glycomimetic, is an antivirulence agent. L-NBDNJ interferes with the expression of proteins regulating cytoskeleton assembly and organization of the host cell. L-NBDNJ has anti-inflammatory and anti-infective effects in models of cystic fibrosis (CF) lung disease infection .
    L-NBDNJ
  • HY-P10432
    SHAAGtide

    		Formyl Peptide Receptor (FPR) Others Inflammation/Immunology
    SHAAGtide is a FPRL1 activator. SHAAGtide has anti-inflammatory activity, mediates its biological activity via FPR2 and is used to reduce the expression of inflammatory cytokines in mouse models. SHAAGtide can be used in the study of diseases such as lung inflammation and fibrosis .
    SHAAGtide
  • HY-158315
    NZ-97

    		Dipeptidyl Peptidase Inflammation/Immunology
    NZ-97 is an inhibitor for dipeptidyl peptidase 4 (DPP4) with an IC50 of 18 nM. NZ-97 exhibits a low initial plasma exposure with Cmax of 0.13 µM, which is eliminated in 8 h. NZ-97 ameliorates damage in the Lipopolysaccharides (HY-D1056)-induced lung injury and Bleomycin (HY-108345)-induced lung fibrosis in mice model .
    NZ-97
  • HY-108858
    Dornase alfa
    1 Publications Verification

    rhDNase

    		 Others Others
    Dornase alfa (rhDNase) is a recombinant human deoxyribonuclease I (rhDNase), an enzyme which selectively cleaves DNA. Dornase alfa hydrolyzes the DNA present in sputum/mucus and reduces viscosity in the lungs, promoting improved clearance of secretions. Dornase alfa plays an important role in cystic fibrosis .
    Dornase alfa
  • HY-109187A
    Posenacaftor sodium
    1 Publications Verification

    PTI-801 sodium

    		 CFTR Inflammation/Immunology
    Posenacaftor (PTI-801) sodium is a cystic fibrosis transmembrane regulator (CFTR) protein modulator that corrects the folding and trafficking of CFTR protein. Posenacaftor sodium is used for the research of cystic fibrosis (CF) .
    Posenacaftor sodium
  • HY-136093B
    Lixumistat

    IM156 free base; HL156A free base; HL271 free base

    		 Mitochondrial Metabolism Cancer
    Lixumistat (IM156) is a novel biguanide mitochondrial protein complex 1 inhibitor of oxidative phosphorylation (OXPHOS) with anti-tumor activity. Lixumistat regulates OXPHOS to attenuate mitochondrial metabolic reprogramming and inhibit lung fibrosis. Lixumistat also suppresses B-cell activation to alleviate systemic lupus erythematosus .
    Lixumistat
  • HY-155328
    GK444

    		HDAC Inflammation/Immunology
    GK444 (Compound 15a) is a HDAC1/2 inhibitor (IC50: 100 and 92 nM for HDAC1/2 respectively). GK444 inhibits Caco-2 cells with IC50 of 4.1 μM. GK444 also reduces TGF-β1 induced COL1A1 mRNA levels in primary normal human lung fibroblasts. GK444 inhibits Bleomycin (HY-108345)-induced lung fibrosis in mice .
    GK444
  • HY-P2780A
    Cathepsin B, Human Liver

    		Apoptosis Cathepsin Pyroptosis Ferroptosis Autophagy Necroptosis Inflammation/Immunology Cancer
    Cathepsin B, Human Liver is a cysteine protease in liver and is involved in multiple kinds of programmed cell death (including apoptosis, pyroptosis, ferroptosis, necroptosis, and autophagic cell death). Cathepsin B (CTSB) have been implicated in various ECM-related disorders, such as dilated cardiomyopathy, lung fibrosis, proteinuric renal disorders, cancer, and osteoporosis .
    Cathepsin B, Human Liver
  • HY-156420
    ATUX-1215

    		Phosphatase Others
    ATUX-1215 is an activator of protein phosphatase 2A (PP2A). ATUX-1215 reduced the phosphorylation of ERK, p38, JNK, and Akt and the secretion of IL-12p70, GM-CSF, and IL1α in BLM-treated animals. ATUX-1215 can slow the progression of lung fibrosis .
    ATUX-1215
  • HY-145390
    Nrf2 activator-1

    		Keap1-Nrf2 Inflammation/Immunology
    Nrf2 activator-1 is a potent activator of NF-E2 related factor 2 (Nrf2). Nrf2 activator-1 has the potential for the research of COPD and other respiratory diseases, including asthma, Acute Lung Injury (ALI), Acute Respiratory Distress Syndrome (ARDS) and pulmonary fibrosis (extracted from patent WO2018109647A1) .
    Nrf2 activator-1
  • HY-137561A
    Bexotegrast hydrochloride

    PLN-74809 hydrochloride

    		 Integrin Inflammation/Immunology
    Bexotegrast hydrochloride (PLN-74809 hydrochloride) is a small molecule dual selective inhibitor with activity targeting αVβ1 and αVβ6. Bexotegrast hydrochloride is used for idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). Bexotegrast hydrochloride inhibits the activation of TGF-β1 by blocking the function of these integrins, thereby preventing the growth of fibrous tissue in the lungs and bile ducts .
    Bexotegrast hydrochloride
  • HY-144743
    ATX inhibitor 12

    		Phosphodiesterase (PDE) Others
    ATX inhibitor 12 (compound 20) is an orally active and potent ATX (autotaxin) inhibitor, with an IC50 of 1.72 nM. ATX inhibitor 12 effectively alleviates lung structural damage with fewer fibrotic lesions at an oral dose of 60 mg/kg in C57Bl/6J mice. ATX inhibitor 12 can be uesd for idiopathic pulmonary fibrosis (IPF) research .
    ATX inhibitor 12
  • HY-15448
    Tezacaftor
    10+ Cited Publications

    VX-661

    		 CFTR Cancer
    Tezacaftor (VX-661) is a F508del CFTR corrector. It helps CFTR protein reach the cell surface. However, Ivacaftor (VX-770, HY-13017), a CFTR potentiator, helps to prolong the opening time of cell surface CFTR protein channels. Tezacaftor combining with Ivacaftor, shows potent efficacy against cystic fibrosis and diseases with homozygous for the CFTR Phe508del mutation. Moreover, Elexacaftor (VX-445, HY-111772) is also a CFTR corrector. Elexacaftor-Tezacaftor-Ivacaftor aims at with cystic fibrosis (CF) with at least one Phe508del mutation, often avoids the indication for lung transplantation .
    Tezacaftor
  • HY-147946
    PDE1-IN-4

    		Phosphodiesterase (PDE) Calcium Channel Inflammation/Immunology
    PDE1-IN-4 (compound 2g) is a potent and selective PDE1 (phosphodiesterase-1) inhibitor, with IC50 values of 10, 145, and 354 nM for PDE1C, PDE1A, and PDE1B, respectively. PDE1-IN-4 inhibits myofibroblast differentiation of human lung fibroblasts induced by TGF-β1. PDE1-IN-4 shows anti-fibrosis effects through the regulation of cAMP (3′,5′-cyclic adenosine monophosphate) and cGMP (3′,5′-cyclic guanosine monophosphate). PDE1-IN-4 can be used for idiopathic pulmonary fibrosis (IPF) research .
    PDE1-IN-4
  • HY-B0486
    Lonidamine
    5+ Cited Publications

    AF-1890; Diclondazolic Acid; DICA

    		 Hexokinase Mitochondrial Metabolism Apoptosis Parasite Inflammation/Immunology Cancer
    Lonidamine (AF-1890) is a hexokinase and mitochondrial pyruvate carrier inhibitor (Ki: 2.5 μM). Lonidamine also inhibits aerobic glycolysis in cancer cells. Lonidamine can be used in the research of mitochondrial metabolism and inflammation, such as pulmonary fibrosis .
    Lonidamine
  • HY-B0486R
    Lonidamine (Standard)

    		Hexokinase Mitochondrial Metabolism Apoptosis Parasite Inflammation/Immunology Cancer
    Lonidamine (Standard) is the analytical standard of Lonidamine. This product is intended for research and analytical applications. Lonidamine (AF-1890) is a hexokinase and mitochondrial pyruvate carrier inhibitor (Ki: 2.5 μM). Lonidamine also inhibits aerobic glycolysis in cancer cells. Lonidamine can be used in the research of mitochondrial metabolism and inflammation, such as pulmonary fibrosis .
    Lonidamine (Standard)
  • HY-14564A
    GTS-21 dihydrochloride
    5+ Cited Publications

    DMXB-A; DMBX-anabaseine

    		 nAChR 5-HT Receptor Inflammation/Immunology
    GTS-21 dihydrochloride is a selective alpha7 nicotinic acetylcholine receptor (α7-nAChR) agonist with anti‑inflammatory and cognition‑enhancing activities. GTS-21 dihydrochloride is also a α4β2 (Ki=20 nM for humanα4β2) and 5-HT3A receptor (IC50=3.1 μM) antagonist .
    GTS-21 dihydrochloride
  • HY-109187B
    (R)-Posenacaftor sodium

    (R)-PTI-801 sodium

    		 CFTR Inflammation/Immunology
    (R)-Posenacaftor (R)-PTI-801) sodium is the R enantiomer of Posenacaftor. Posenacaftor is a cystic fibrosis transmembrane regulator (CFTR) protein modulator that corrects the folding and trafficking of?CFTR?protein. Posenacaftor is used for the research of cystic fibrosis (CF) .
    (R)-Posenacaftor sodium
  • HY-109187
    Posenacaftor

    PTI-801

    		 CFTR Inflammation/Immunology
    Posenacaftor (PTI-801) is a cystic fibrosis transmembrane regulator (CFTR) protein modulator that corrects the folding and trafficking of CFTR protein. Posenacaftor is used for the research of cystic fibrosis (CF) .
    Posenacaftor
  • HY-14564
    GTS-21

    		nAChR 5-HT Receptor Inflammation/Immunology
    GTS-21 dihydrochloride is a selective alpha7 nicotinic acetylcholine receptor (α7-nAChR) agonist with anti‑inflammatory and cognition‑enhancing activities. GTS-21 dihydrochloride is also a α4β2 (Ki=20 nM for humanα4β2) and 5-HT3A receptor (IC50=3.1 μM) antagonist. GTS-21 can be used in age-associated memory impairment (AAMI) and Alzheimer's disease research .
    GTS-21
  • HY-I0501
    2'-Aminoacetophenone

    o-aminoacetophenone

    		 Bacterial Apoptosis Atg8/LC3 p62 Autophagy Infection Inflammation/Immunology
    2'-Aminoacetophenone is an orally active inducer of apoptosis and respiratory biomarker. 2'-Aminoacetophenone can be used to detect Pseudomonas aeruginosa infections in the lungs of cystic fibrosis patients. 2'-Aminoacetophenone can inhibit the protein levels of LC3BII and p62 in macrophages infected with pqsA or mvfR and regulate autophagy. 2'-Aminoacetophenone can disrupt mitochondrial function by inducing oxidative stress and apoptosis signaling, leading to dysfunction in mouse skeletal muscle .
    2'-Aminoacetophenone
  • HY-18758
    IN-1130
    1 Publications Verification

    		 TGF-β Receptor Inflammation/Immunology Cancer
    IN-1130 is a highly selective transforming growth factor-β type I receptor kinase (ALK5) inhibitor with an IC50 of 5.3 nM for ALK5-mediated Smad3 phosphorylation. IN-1130 inhibits ALK5 phosphorylation of casein (IC50=36 nM) and p38α mitogen-activated protein kinase (IC50=4.3 μM). IN-1130 suppresses renal fibrosis in obstructive nephropathy and blocks breast cancer lung metastasis .
    IN-1130
  • HY-W010572
    1-Thioglycerol

    alpha-Thioglycerol

    		 Biochemical Assay Reagents Others
    1-Thioglycerol, commonly used as a reducing agent in various biochemical and biophysical applications, especially in protein chemistry and molecular biology, it can protect proteins from oxidation and denaturation, and can reduce disulfide bonds to thiols base, which can then be modified or analyzed. In addition, 1-Thioglycerol has been investigated for potential medical applications, including as an inhibitor of cystic fibrosis, which may help improve the function of lung cells, and has also been studied for Used in the preparation of metal nanoparticles and as a stabilizer for certain pharmaceutical preparations.
    1-Thioglycerol
  • HY-12678S
    Entrectinib-d4

    NMS-E628-d4; RXDX-101-d4

    		 ROS Kinase Trk Receptor Anaplastic lymphoma kinase (ALK) Autophagy Isotope-Labeled Compounds Cancer
    Entrectinib-d4 (NMS-E628-d4; RXDX-101-d4) is the deuterium labeled Entrectinib (HY-12678). Entrectinib is an orally active, BBB-penetrated and centrally active inhibitor of TrkA/B/C, ROS1 and ALK, with IC50 values of 1, 3, 5, 12 and 7 nM, respectively. Entrectinib induces apoptosis and cycle arrest in cancer cells, has antitumor activity, and attenuates bleomycin-induced lung fibrosis in mice .
    Entrectinib-d4
  • HY-149136
    MORF-627

    		Integrin TGF-beta/Smad Inflammation/Immunology
    MORF-627 is a selective, orally active inhibitor for integrin αvβ6 with an IC50 of 9.2 nM measuring by human serum ligand binding assay. MORF-627 inhibits αvβ6-mediated TGF-β1 activation with an IC50 of 2.63 nM, inhibits SMAD2/3 phosphorylation with an IC50 of 8.3 nM. MORF-627 ameliorates the Bleomycin (HY-108345)-induced mouse lung fibrosis .
    MORF-627
  • HY-P10226
    PGD97

    		Chloride Channel CFTR Endocrinology
    PGD97 is a selective cyclic peptide inhibitor against CAL/CFTR interactions, with a KD value of 6 nM towards the CAL PDZ domain for its desulfide cyclized form. PGD97 (desulfide cyclized form) has selectivity ≥ 130-fold compared to NHERF1/2 PDZ domains. PGD97 is capable of stabilizing F508del-CFTR at the cell membrane and improving CFTR function required for proper fluid homeostasis in tne lung. PGD97 can be used for the research of cystic fibrosis .
    PGD97
  • HY-12678S1
    Entrectinib-d8

    NMS-E628-d8; RXDX-101-d8

    		 Isotope-Labeled Compounds Autophagy Anaplastic lymphoma kinase (ALK) Trk Receptor ROS Kinase Cancer
    Entrectinib-d8 (NMS-E628-d8; RXDX-101-d8) is a deuterated version of Entrectinib (HY-12678). Entrectinib (NMS-E628) is an orally available, blood-brain barrier permeable, central nervous system active TrkA/B/C, ROS1 and ALK inhibitor with IC50 values of 1, 3, 5, 12 and 12, respectively. 7 nM. Entrectinib induces apoptosis and cycle arrest in cancer cells, has anti-tumor activity, and also alleviates bleomycin-induced pulmonary fibrosis in mice .
    Entrectinib-d8
  • HY-P1624
    Teduglutide
    1 Publications Verification

    ALX-0600

    		 Nuclear Hormone Receptor 4A/NR4A FXR Inflammation/Immunology
    Teduglutide (ALX-0600) is an analog of human glucagon like peptide-2 (GLP-2). Teduglutide can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal FXR signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis .
    Teduglutide
  • HY-P1624A
    Teduglutide TFA

    ALX-0600 TFA

    		 Nuclear Hormone Receptor 4A/NR4A FXR Inflammation/Immunology
    Teduglutide TFA is a dipeptidyl peptidase IV resistant glucagon-like peptide 2 (GLP-2) analogue. Teduglutide TFA can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal FXR signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide TFA can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis .
    Teduglutide TFA
  • HY-P2797
    Chitinase, Serratia marcescens

    AMCase, Serratia marcescens

    		 Bacterial Metabolic Disease Inflammation/Immunology
    Chitinase, Serratia marcescens (EC 3.2.1.14) has partial lysozyme activity and is widely found in bacteria, fungi, animals and some plants. Chitinase belongs to the glycosyl hydrolase family. Chitinase catalyzes chito-oligosaccharide hydrolysis. Chitinases also can serve as prognostic biomarkers of disease progression. Chitinase can be used in the research of pathogenesis of various human fibrotic and inflammatory disorders, particularly those of the lung (idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, sarcoidosis, and asthma) and the gastrointestinal tract (inflammatory bowel diseases (IBDs) and colon cancer) .
    Chitinase, Serratia marcescens

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: